NICE to review guidance on Servier's Protelos after legal challenge
This article was originally published in Scrip
The health technology appraisal body for England and Wales, NICE, will have to review its guidance on Servier's Protelos (strontium ranelate) for preventing osteoporotic fragility fractures, said a UK judge last week. Moreover, NICE must be clear in its reasoning when it reaches a different conclusion from that of "eminent bodies" such as the European Medicines Agency (EMA), according to the judgement.
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.